Jump to content
Advertisement

Advertisement

All Activity

This stream auto-updates

  1. Yesterday
  2. Turns out there's a 'natural' way to poo, and we've been doing it wrong our whole lives Why we should all be adjusting our poop position. BY LUCY MORGAN 21 OCTOBER 2021 How do you poo? Trust us, it's important, as it turns out the ‘poop position’ that most of us are used to (sitting on a toilet with our feet on the floor) might not be so good for our bodies or our overall health. Back in 2017 (good times), Squatty Potty released a video, which quickly went viral as it featured an ice-cream-pooping unicorn called Dookie who demonstrated exactly how we should all be pooing. Grossed out yet? Stick with us. We all care about our health and wellbeing, yet research shows that so many of us are still struggling with bowel-related issues, including irritable bowel syndrome(IBS) and constipation. Bupa estimate that between one and two in 10 people have IBS, while constipation is thought to be twice as common in women as it is in men. We're not saying adjusting your poop position will definitely ease bowel-related issues, but it can't hurt to know the facts, right? >> Read Full article © Condé Nast Britain 2021.
  3. Last week
  4. Hello, I am French and I am launching a bit of a SOS, since 3 days I think I suffer from Splenic flexure syndrome, it is very painful, in France we already know very badly ibs-c, tomorrow I'm going to see the doctor, but I'm afraid he tells me it's psychological, what medication can we take against the pain? I have intermittent burns in my left arm to the point that I have to put it in a sling like a broken arm, and I have pain that radiates directly from the spine at times, but also when I walk quickly, during the crises I also have pain under the armpits I suffer ibs-c with very hard stools.thank you.
  5. drseangoldendc

    drseangoldendc

    While I am an integrative health practitioner, nothing I say on this forum should be taken as medical advice, and I do not know your personal medical history. Everything should be taken for informational purposes only, and speak with your health care provider before making any changes in supplements, diets, or medications. You can learn more about me and how I help others (along with free resources) at www.goldenhealthmethod.com

  6. Hi Esjie, Thanks very much for the info. The calcium carbonate causes constipation for me. It's hard to find bok choy in Puerto Rico. But I am trying to eat a lot more kale, arugula, and other dark leafy greens. I'm glad to hear you have found some dairy foods that you can tolerate. I try to avoid butter because of the high cholesterol content. take good care, Diane
  7. Study: Chronic GI Disorders Surfaced Months After COVID MedPage Today Four in 10 COVID-19 patients from disadvantaged communities developed new post-COVID gastrointestinal disorders, including functional dyspepsia (FD) and irritable bowel syndrome (IBS), researchers found in a retrospective study. In a survey of 200 individuals, 39.5% developed de novo post-COVID gastrointestinal disorders, with 58 reporting FD-like complaints, two reporting IBS-like complaints, and 19 reporting both, according to researchers led by Christopher Vélez, MD, of the Massachusetts General Hospital in Boston, and colleagues. View the full article
  8. Good for you @Jeffrey Roberts I am pleased to hear that. You would have my vote...but there is a hitch. I saw this too late, so sorry. I went there but the voting is closed now. I think results are 24 October? Wishing you the best of luck.
  9. @Saphire7 Have you tried a calcium supplement as well as the normal food you eat? A Calcium supplement should be safe so long as you don't exceed the RDA (including what you get from foods) Please do check this, but I think the RDA is 1200 with upper limit 2000mg daily. It might be wise to ask your doctor though before doing that. I think vitamin D3 also helps the absorption of Calcium. I have also heard that Calcium carbonate can help IBS-D perhaps. I am not diagnosed as lactose intolerant, and within limits, lactose doesn't upset my gut. I eat butter, but haven't used other milk-based products for a very long time, and that wasn't because of IBS, as I went off milky things a long time ago, when my gut was okay. I have never been able to like yogurt. Occasionally I eat a bit of mild cheese because I do like that, but sometimes it doesn't always agree with me if I eat too much. But butter always seems to suit me. I take one calcium tablet a day which is 500mg. And Bok Choy (low FODMAP) is packed with calcium. 1 cup lightly steamed contains 158mg. I have IBS D too, and have always found that vegetable to be very gentle on my gut.
  10. Endometriosis and irritable bowel syndrome Contemporary Obgyn A systemic review and meta-analysis in the Archives of Gynecology and Obstetrics has found epidemiological evidence that endometriosis and irritable bowel syndrome (IBS) are connected. Women with endometriosis are roughly twice as likely to develop IBS than women without endometriosis, according to the review. The literature search was performed using the electronic databases MEDLINE and EMBASE from 1990 to November 2019. The search yielded 11 studies for inclusion: two prospective cohort studies, two retrospective cohort studies, four case-control studies, one cross-sectional study and two clinical series. Two studies were conducted in the United States, two in the United Kingdom, three in Europe (Netherlands, Denmark and Sweden) and one each in New Zealand, Australia, Taiwan and Egypt. View the full article
  11. Hello Dogmom899, We have heard from a lot of people who actually switched from Amitiza to Linzess because of the amount of nausea that they found with Amitiza. It's interesting that you are going in the other direction. Perhaps that's a good sign and that Amitiza will work for you better than Linzess.
  12. Neurogastroenterol Motil. 2021 Oct 20:e14279. doi: 10.1111/nmo.14279. Online ahead of print. ABSTRACT BACKGROUND: Nocebo effects occurring in patients receiving placebo frequently impact on adverse events reported in randomized controlled trials (RCTs) in irritable bowel syndrome (IBS). Therefore, we conducted a systematic review and meta-analysis to assess the proportion of patients randomized to placebo or active drug experiencing any adverse event in trials of licensed drugs for IBS with constipation (IBS-C) or diarrhea (IBS-D), and to estimate the risk of developing adverse events among patients randomized to placebo. METHODS: We searched MEDLINE, EMBASE CLASSIC and EMBASE, and the Cochrane central register of controlled trials (through June 2021) to identify RCTs comparing licensed drugs with placebo in adults with IBS-C or IBS-D. We generated Forest plots of pooled adverse event rates in both active drug and placebo arms and pooled risk differences (RDs) with 95% confidence intervals (CIs). KEY RESULTS: There were 21 RCTs of licensed drugs versus placebo in IBS-C (5953 patients placebo) and 17 in IBS-D (3854 patients placebo). Overall, 34.9% and 46.9% of placebo patients in IBS-C and IBS-D trials, respectively, developed at least one adverse event, with a statistically significantly higher risk of any adverse event and withdrawal due to an adverse event with active drug. In IBS-C and IBS-D trials, rates of each individual adverse event were generally higher with active drug. However, in IBS-C trials, only diarrhea or headache was significantly more common with active drug (RD 0.066 (95% CI 0.043-0.088) and RD 0.011 (95% CI 0.002-0.021), respectively), and in IBS-D trials only constipation, nausea, or abdominal pain (RD 0.096 (95% CI 0.054-0.138), 0.014 (95% CI 0.002-0.027), and 0.018 (95% CI 0.002-0.034), respectively). CONCLUSIONS & INFERENCES: Patients with IBS randomized to placebo have a high risk of reporting adverse events, which might relate to both nocebo and non-nocebo factors. Although patients' expectations and psychosocial factors may be involved, further understanding of the mechanisms are important to control or optimize these effects in RCTs, as well as in clinical practice. PMID:34672052 | DOI:10.1111/nmo.14279 View the full article
  13. J Gastroenterol Hepatol. 2021 Oct 20. doi: 10.1111/jgh.15717. Online ahead of print. ABSTRACT BACKGROUND: Since acute infectious gastroenteritis may cause post-infection irritable bowel syndrome (PI-IBS) and functional dyspepsia (FD) and the Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) affects gastrointestinal (GI) tract, Corona Virus Disease-19 (COVID-19) may cause PI-functional GI disorders (FGID). We prospectively studied the frequency and spectrum of PI-FGIDs among COVID-19 and historical healthy controls and the risk factors for its development. METHODS: 280 patients with COVID-19 and 264 historical healthy controls were followed up at 1, and 3 months using translated validated Rome Questionnaires for the development of chronic bowel dysfunction (CBD), dyspeptic symptoms, and their overlap and at 6-month for IBS, uninvestigated dyspepsia (UD) and their overlap. Psychological comorbidity was studied using Rome III Psychosocial Alarm Questionnaire. RESULTS: At 1-, and 3-months, 16 (5.7%), 16 (5.7%), 11 (3.9%) and 24 (8.6%), 6 (2.1%), 9 (3.2%) of COVID-19 patients developed CBD, dyspeptic symptoms, and their verlap, respectively; among healthy controls, none developed dyspeptic symptoms and one developed CBD at 3-month (p<0.05). At six-month, 15 (5.3%), 6 (2.1%), and 5 (1.8%) 280 COVID-19 patients developed IBS, UD, and IBS-UD overlap, respectively and one healthy control developed IBS at 6-months (p<0.05 for all except IBS-UD overlap). The risk factors for post-COVID-19 FGIDs at 6-month included symptoms (particularly GI), anosmia, ageusia, and presence of CBD, dyspeptic symptoms, or their overlap at one and 3-months and the psychological comorbidity. CONCLUSIONS: This is the first study showing COVID-19 lead to post-COVID-19 FGIDs. Post-COVID-19 FGIDs may pose a significant economic, social, healthcare burden to the world. PMID:34672022 | DOI:10.1111/jgh.15717 View the full article
  14. So my doctor prescribed me Amitiza today and I was wondering what others peoples experiences were with it? I have previously tried Linzess twice and it worked, but too well, and each time I ended up severely dehydrated and nauseous while constantly running for the restroom. I'm hoping Amitza will relieve my IBS-C without any bad side effects because Linzess was nothing I could take and go to work for sure.
  15. Greetings, I am lactose intolerant and also have osteoporosis. I had mostly given up on dairy products but was thinking of trying an enzyme product that helps digest lactose like Fast Act. So I was wondering if anyone in the group has tried any products that help digest lactose. I find it hard to consume enough calcium by only consuming green vegetables, fish w/ bones, certain beans, oranges etc. It seems like if I could digest yogurt, for example, I would be able to get the RDA of calcium. Thanks for any ideas you may have on this subject. Have a good day!
  16. I need information about what to eat and what not to eat for IBS... I'm suffering!
  17. Earlier
  18. Gastroenterol Hepatol Bed Bench. 2021 Fall;14(4):304-310. ABSTRACT AIM: This pilot study assessed the benefits of an adjuvant low FODMAP diet (LFD) in adult CD patients established on GFD who had a normal remission biopsy. BACKGROUND: Patients with biopsy-proven adult celiac disease (CD) may have on-going gastrointestinal symptoms despite adherence to a gluten-free diet (GFD). Functional gut symptoms, including irritable bowel syndrome (IBS), is one cause of persistent symptoms in CD patients. METHODS: Twenty-five adult CD patients who were adherent to the GFD were recruited. These patients had histologically normal villi on their remission biopsy. A specialist dietitian then offered an adjuvant LFD. Symptom response was assessed using the Gastrointestinal Symptom Rating Scale (GSRS) from baseline to follow up. RESULTS: Of the 25 CD patients in remission with concurrent IBS, 9 did not wish to pursue the LFD, and 1 had incomplete data. Fifteen patients completed a minimum of four weeks on the LFD (mean age 44 ± 17.3; range 43.2 years; median duration of CD follow-up 7.2 years). Global relief of gut symptoms was reported by 8/15 patients (53% p = 0.007). Significant reductions in abdominal pain (p <0.01), distension (p < 0.02), and flatulence (p <0.01) were demonstrated. CONCLUSION: This is the first study to demonstrate that an adjunct LFD is an effective dietary treatment for concurrent IBS in adult CD patients with biopsy-confirmed remission. Such patients should be seen by a specialist dietitian to ensure nutritional adequacy and appropriate reintroduction of FODMAP-containing foods. PMID:34659657 | PMC:PMC8514221 View the full article
  19. Low FODMAP vermicelli bowl with peanut sauce 😍🥜 One of our favourite quick and easy lunches - great for meal prep and takes no time at all to put together! 🍜 https://www.monashfodmap.com/recipe/tofu-vermicelli-bowl-peanut-sauce/ (Feed generated with FetchRSS)View the full article
  20. RT @MASTprogram: Take home messages from #FNCE2021 via @AliRezaieMD #FNCE (Feed generated with FetchRSS)View the full article
  21. RT @MASTprogram: Q: What do you recommend to patients who you suspect that they have #SIBO but have difficulty finding a practitioner who will test for it? A: https://pubmed.ncbi.nlm.nih.gov/28323273/ https://journals.lww.com/ajg/fulltext/2020/02000/acg_clinical_guideline__small_intestinal_bacterial.9.aspx #FNCE (Feed generated with FetchRSS)View the full article
  22. Esjie

    Ibs Flare Up.

    Dolphin500 .....lots of kind wishes for you. I just read your other post. 💓
  23. Esjie

    I need a colostomy

    My kind thoughts and wishes Dolphin500. I am sorry you are going through this. Hugs.
  24. Here's How My Unmanageable IBS as a Teen Led to My First Colonoscopy as an Adult POPSUGAR The word "colonoscopy" has always been one I have dreaded hearing. At 14, I was diagnosed by a gastroenterologist with irritable bowel syndrome (IBS), which causes stomach pain and other intestinal symptoms, like bloating and diarrhea. These symptoms tend to happen at the same time, which causes a lot of discomfort. When I was diagnosed with IBS, I was given a prescription for fiber bars and sent on my way with the suggestion that my condition was brought on by stress (not surprising since I was in high school). I took an antidiarrheal medication when I could and eventually learned that changes in diet could help me immensely — which drove me toward vegetarianism and then veganism. View the full article
  25. Steven Wright is a gut health specialist who invested over $400,000 to study, understand and heal his gut microbiome. Through that process, he developed Healthy Gut and three tailored supplements to help restore the gut ecosystem and help others who suffer from SIBO, IBS, diarrhea, soft stool, constipation, bloating, IBD and other digestive issues. Learn more about how butyrate, betaine HCl and digestive enzymes can help you recover from your gut health issues on The Perfect Stool Podcast with host Lindsey Parsons, EdD. Listen below or find the podcast version at: https://link.chtbl.com/theperfectstool-IBS <iframe title="Embed Player" style="border: medium none;" src="//play.libsyn.com/embed/episode/id/20796221/height/200/theme/modern/size/large/thumbnail/yes/custom-color/87A93A/time-start/00:00:00/download/no/hide-show/no/direction/backward/hide-playlist/no/hide-subscribe/no/hide-share/no" scrolling="no" allowfullscreen="" webkitallowfullscreen="true" mozallowfullscreen="true" oallowfullscreen="true" msallowfullscreen="true" width="100%" height="200"></iframe>
  26. Thank you all! I've been taking Linzess for 1 week now and the fatigue is a bit much right now and I also wish they would add that to the side effects, I used to have to take a sleep aide to go to sleep at night and now I don't and when I get up the next morning I'm so tired and sluggish. I'm not sure how long this is going to last.
  27. A Modest Solution for Pediatric Constipation Gastroenterology & Endoscopy News The use of mHealth innovations has experienced an explosive scientific evolution and ubiquitous uptake by patients over the past two decades. Many of these tools have been designed for niche indications to assist clinicians in the outpatient setting or to complement the care of patients at home. The work described by Dr. Rao’s team highlights one of the most difficult chronic conditions for pediatric and adult gastroenterologists to manage: constipation and fecal incontinence. These cutting-edge apps allow for the objective capture of specific patient-related data points that can better inform care and, we hope, improve clinical and patient-related outcomes. View the full article
  28. Therap Adv Gastroenterol. 2021 Oct 8;14:17562848211048133. doi: 10.1177/17562848211048133. eCollection 2021. ABSTRACT BACKGROUND: Aloe barbadensis Mill. (Aloe) extract was found to be well-tolerated, safe and showed beneficial effects in subsets of irritable bowel syndrome (IBS) patients in two randomized, double-blind, controlled studies. However, the individual studies were underpowered to perform subgroup analyses. We therefore determined the effect of Aloe extract in IBS subgroups in a post hoc analysis combining the results from the two studies. METHODS: Data from the two controlled studies comparing Aloe and control treatment taken orally for 4 weeks, were pooled. Both studies included IBS patients fulfilling the ROME III criteria and IBS Symptom Severity Score (IBS-SSS) was assessed. We analysed the effect of Aloe extract on IBS symptom severity and the proportion of responders (IBS-SSS reduction ⩾ 50) in IBS subgroups. RESULTS: In total, 213 IBS patients were included in the post hoc subgroup analyses. A reduction in overall symptom severity, primarily driven by effect on pain severity and frequency, comparing baseline versus end of treatment, was recorded in IBS patients with diarrhoea (IBS-D) receiving Aloe (n = 38, p < 0.001) but not control treatment (n = 33, p = 0.33), with difference between the treatment groups (p = 0.01). Moreover, the frequency of responders was higher in IBS-D patients receiving Aloe (n = 22, 58%) compared to control treatment (n = 10, 30%) (p = 0.02). The effect of Aloe extract treatment on IBS symptom severity was not superior to control treatment in the other IBS subtypes. CONCLUSION: Aloe extract improves symptom severity in IBS-D patients and can be regarded as a safe and effective treatment option for this patient group. PMID:34646359 | PMC:PMC8504273 | DOI:10.1177/17562848211048133 View the full article
  1. Load more activity
×
×
  • Create New...